elafibranor

Details

Key Milestones2
Call for patient/clinician input open18-Oct-24
Call for patient/clinician input closed13-Dec-24
Submission received27-Nov-24
Submission accepted11-Dec-24
Review initiated12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment06-Mar-25
Deadline for sponsors comments18-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor09-Apr-25
Expert committee meeting (initial)23-Apr-25
Draft recommendation issued to sponsorMay 05, 2025
To
May 07, 2025
Draft recommendation posted for stakeholder feedback15-May-25
End of feedback period30-May-25

pemigatinib

Details

Key Milestones2
Call for patient/clinician input open18-Oct-24
Call for patient/clinician input closed13-Dec-24
Submission received18-Oct-24
Submission accepted01-Nov-24
Review initiated04-Nov-24
Draft CADTH review report(s) provided to sponsor for comment20-Jan-25
Deadline for sponsors comments30-Jan-25
CDA-AMC review report(s) and responses to comments provided to sponsor28-Feb-25
Expert committee meeting (initial)12-Mar-25
Draft recommendation issued to sponsor26-Mar-25
Draft recommendation posted for stakeholder feedback03-Apr-25
End of feedback period17-Apr-25
Final recommendation issued to sponsor and drug plans05-May-25
Final recommendation posted-
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)20-May-25
CDA-AMC review report(s) posted-

dabrafenib trametinib

Details

Key Milestones2
Submission received11-Oct-24
Review initiated11-Oct-24
Expert committee meeting (initial)20-Mar-25
Draft recommendation posted for stakeholder feedback11-Apr-25
End of feedback period29-Apr-25
Final recommendation posted-
CDA-AMC review report(s) posted-

Dabrafenib trametinib

Details

Key Milestones2
Submission received17-Oct-24
Review initiated17-Oct-24
Expert committee meeting (initial)20-Mar-25
Draft recommendation posted for stakeholder feedback11-Apr-25
End of feedback period29-Apr-25
Final recommendation posted-
CDA-AMC review report(s) posted-

polatuzumab vedotin

Details

Key Milestones2
Call for patient/clinician input open17-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received27-Nov-24
Submission accepted11-Dec-24
Review initiated12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment09-Apr-25
Deadline for sponsors comments15-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor02-May-25
Expert committee meeting (initial)14-May-25
Draft recommendation issued to sponsorMay 27, 2025
To
May 29, 2025
Draft recommendation posted for stakeholder feedback05-Jun-25
End of feedback period19-Jun-25

pembrolizumab

Details

Key Milestones2
Call for patient/clinician input open17-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received27-Nov-24
Submission accepted11-Dec-24
Review initiated12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment26-Mar-25
Deadline for sponsors comments04-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor02-May-25
Expert committee meeting (initial)14-May-25
Draft recommendation issued to sponsorMay 27, 2025
To
May 29, 2025
Draft recommendation posted for stakeholder feedback05-Jun-25
End of feedback period19-Jun-25

belzutifan

Details

Key Milestones2
Call for patient/clinician input open11-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received25-Nov-24
Submission accepted09-Dec-24
Review initiated10-Dec-24
Draft CADTH review report(s) provided to sponsor for comment25-Mar-25
Deadline for sponsors comments03-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor02-May-25
Expert committee meeting (initial)14-May-25
Draft recommendation issued to sponsorMay 27, 2025
To
May 29, 2025
Draft recommendation posted for stakeholder feedback05-Jun-25
End of feedback period19-Jun-25

leuprolide mesylate

Details

Key Milestones2
Call for patient/clinician input open11-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received22-Nov-24
Submission accepted06-Dec-24
Review initiated09-Dec-24
Draft CADTH review report(s) provided to sponsor for comment18-Mar-25
Deadline for sponsors comments27-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor02-May-25
Expert committee meeting (initial)14-May-25
Draft recommendation issued to sponsorMay 27, 2025
To
May 29, 2025
Draft recommendation posted for stakeholder feedback05-Jun-25
End of feedback period19-Jun-25

pembrolizumab

Details

Key Milestones2
Call for patient/clinician input open04-Oct-24
Call for patient/clinician input closed02-Dec-24
Submission received14-Nov-24
Submission accepted28-Nov-24
Review initiated29-Nov-24
Draft CADTH review report(s) provided to sponsor for comment21-Feb-25
Deadline for sponsors comments04-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor28-Mar-25
Expert committee meeting (initial)09-Apr-25
Draft recommendation issued to sponsor23-Apr-25
Draft recommendation posted for stakeholder feedback01-May-25
End of feedback period15-May-25